Pimethixene is an antihistamine and anticholinergic of the thioxanthene chemical class originally developed to treat hyperactivity,[1] anxiety, sleep disorders, and allergy. It is also used for anesthesia and as a bronchodilator (to dilate the bronchi and bronchioles for more airflow).
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral, nasal |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.005.675 |
| Chemical and physical data | |
| Formula | C19H19NS |
| Molar mass | 293.43 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
In combination with pholcodine, it was sold in France by Laboratoires Salvoxyl in the 1970s as the antitussive Salvodex.[2] Pimethixene alone is still available in Brazil under the trade name Muricalm.
In addition to its other activities, it is a highly potent but non-selective serotonin 5-HT2B receptor antagonist.[3] The selective serotonin 5-HT2B receptor antagonist BF-1 was derived from pimethixene.[3]
See also
editReferences
edit- ↑ Chefneux A (July 1978). "[New treatment of hyperkinesis in the child: pimethixene]". Revue Médicale de Liège. 33 (14): 500–3. PMID 674966.
- ↑ Bailly, Christian (8 December 2020). "Salvodex® (9-(1-methyl, 4-piperylidenyl)thiaxanthene and pholcodine), from Laboratoires Salvoxyl (Orléans), 1971". Oncowitan. Retrieved 4 January 2022.
- 1 2 Schmitz B, Ullmer C, Segelcke D, Gwarek M, Zhu XR, Lübbert H (March 2015). "BF-1--a novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs". Eur J Pharmacol. 751: 73–80. doi:10.1016/j.ejphar.2015.01.043. PMID 25666387.
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by adding missing information. |